You are here

Novel Intracellular Therapeutic Agent for Botulinum Intoxication

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI075709-01A2
Agency Tracking Number: AI075709
Amount: $243,590.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PHYSICAL SCIENCES INC 20 NEW ENGLAND BUSINESS CENTER
ANDOVER, MA 01810
United States
DUNS: 073800062
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 () -
Business Contact
Phone: (978) 689-0003
Email: sasso@psicorp.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Biodefense toxins such as ricin, botulinum neurotoxins, and Shiga toxin are a source of concern for terrorist attacks due to their high toxicity and the limited post-exposure treatment alternatives. Each of these protei
n toxins exhibits an enzymatic activity that is the basis of its toxicity. Inhalation and ingestion are the primary routes of entry for protein toxins, and once these molecules have entered the cell, treatment options are severely limited. Physical Science
s Inc. (PSI) proposes to develop highly specific binding agents that will inhibit the catalytic activity of botulinum neurotoxins (BoNT). The proposed novel therapeutics will incorporate materials and methods for efficient delivery of the agents to the cyt
oplasm of target cells thus reversing inhibition of neurotransmitter release. Phase I research will develop novel BoNT inhibitors and demonstrate their efficacy using both in vitro and cell-based assays. In Phase II the agents and delivery vehicles will be
optimized and will be tested for their ability to prevent or reverse the effects of BoNT intoxication in live animal models. We anticipate that the proposed system will deliver sufficient quantities of therapeutic to the cytoplasm to increase the LD50 of
the agents at least 10-fold and significantly reduce recovery time for BoNT exposure. PUBLIC HEALTH RELEVANCE: Post-exposure treatment options for protein toxins such as ricin and botulinum are limited. This research seeks to develop post-exposure therapie
s for protein toxin exposure that will greatly improve survival rates.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government